ReviewEULAR rheumatology open2026
Does effective therapy of psoriasis prevent the development of psoriatic arthritis?
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis frequently precedes psoriatic arthritis (PsA), delineating a tractable window for disease interception. This narrative review integrates mechanistic, imaging, and clinical evidence, together with expert interpretation, to examine whether effective treatment of psoriasis may modify the risk of PsA development. Converging immunopathogenic insights link skin and joint inflammation through interleukin (IL)-23/IL-17-driven pathways, enthesis-synovium crosstalk, and tissue-resident memory T-cell biology. Clinically, progression from psoriasis with arthralgia to PsA occurs in ∼20% of patients within 3 years, typically manifesting with peripheral, synovitis-predominant presentations. Imaging refines short-term risk stratification, with structural entheseal lesions, particularly erosions and new bone formation, representing the most consistent markers of transition. Observational data suggest that biologic therapies used for psoriasis may reduce PsA evolution, with the most consistent evidence for IL-23 pathway blockade. Metabolic factors, notably obesity and weight loss, further modify disease risk, underscoring the role of systemic inflammation and metabolic-immune crosstalk. Together, these findings support the biological plausibility of PsA prevention and justify ongoing interception trials in high-risk psoriasis populations defined by arthralgia and subclinical musculoskeletal inflammation. Robust longitudinal studies integrating biological, imaging, and pragmatic outcomes will be essential to establish causality and define scalable strategies to alter the natural history of psoriatic disease.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.